Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308134815> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4308134815 endingPage "A348" @default.
- W4308134815 startingPage "A348" @default.
- W4308134815 abstract "Abstract Evidence from nonclinical studies suggests a role of cannabinoid-1 receptor (CB1) in the development of diabetic nephropathy (DN). Kidney CB1 expression is upregulated in podocytes and tubular cells in murine models of obesity and diabetes mellitus (DM). Inhibition by CB1 inverse agonists has been shown to ameliorate diabetes-induced albuminuria, inhibit kidney fibrosis and inflammation, and prevent podocyte dysfunction. Mouse models of DM have shown that genetic deletion of CB1 in podocytes or proximal tubular cells protects against glomerular and tubular dysfunction. GFB-024 is a recombinant humanized monoclonal antibody functioning as a CB1-specific inverse agonist. Pharmacodynamic studies demonstrated that GFB-024 protects human podocytes in vitro. Targeting the CB1 pathway with GFB-024 is a potentially novel approach to protecting podocytes from injury in patients with CB1-associated DN. In a phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) trial, we evaluated the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GFB-024 in up to 56 healthy overweight and obese (BMI 25–40 kg/m2) participants. A total of 38 subjects have completed 5 cohorts in the SAD, receiving single doses of 5 mg to 300 mg administered subcutaneously. GFB-024 was well tolerated, and there were no dose-limiting adverse effects. PK exposures achieved in the trial exceeded the estimated efficacious exposure, based on four different in vitro activity assays. Absorption was prolonged with flat exposure over the first 7 days, with a Tmax ranging from approximately 4-7 days. Elimination half-life was approximately 12-13 days, with exposures remaining in the estimated efficacious range at 28 days for all but the lowest dose tested. In summary, GFB-024 was safe and well tolerated following single doses of up to 300 mg. PK analysis demonstrated potentially efficacious exposure, a prolonged absorption phase, and elimination half-life compatible with once-monthly dosing. Presentation: Saturday, June 11, 2022 11:45 a.m. - 12:00 p.m." @default.
- W4308134815 created "2022-11-08" @default.
- W4308134815 creator A5003872915 @default.
- W4308134815 creator A5005918045 @default.
- W4308134815 creator A5026851541 @default.
- W4308134815 creator A5042945644 @default.
- W4308134815 creator A5059630930 @default.
- W4308134815 creator A5075051978 @default.
- W4308134815 creator A5087903486 @default.
- W4308134815 creator A5089381302 @default.
- W4308134815 date "2022-11-01" @default.
- W4308134815 modified "2023-09-26" @default.
- W4308134815 title "OR03-2 Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus" @default.
- W4308134815 doi "https://doi.org/10.1210/jendso/bvac150.723" @default.
- W4308134815 hasPublicationYear "2022" @default.
- W4308134815 type Work @default.
- W4308134815 citedByCount "1" @default.
- W4308134815 countsByYear W43081348152023 @default.
- W4308134815 crossrefType "journal-article" @default.
- W4308134815 hasAuthorship W4308134815A5003872915 @default.
- W4308134815 hasAuthorship W4308134815A5005918045 @default.
- W4308134815 hasAuthorship W4308134815A5026851541 @default.
- W4308134815 hasAuthorship W4308134815A5042945644 @default.
- W4308134815 hasAuthorship W4308134815A5059630930 @default.
- W4308134815 hasAuthorship W4308134815A5075051978 @default.
- W4308134815 hasAuthorship W4308134815A5087903486 @default.
- W4308134815 hasAuthorship W4308134815A5089381302 @default.
- W4308134815 hasBestOaLocation W43081348151 @default.
- W4308134815 hasConcept C126322002 @default.
- W4308134815 hasConcept C134018914 @default.
- W4308134815 hasConcept C148001335 @default.
- W4308134815 hasConcept C170493617 @default.
- W4308134815 hasConcept C2776174234 @default.
- W4308134815 hasConcept C2778938600 @default.
- W4308134815 hasConcept C555293320 @default.
- W4308134815 hasConcept C71924100 @default.
- W4308134815 hasConcept C98274493 @default.
- W4308134815 hasConceptScore W4308134815C126322002 @default.
- W4308134815 hasConceptScore W4308134815C134018914 @default.
- W4308134815 hasConceptScore W4308134815C148001335 @default.
- W4308134815 hasConceptScore W4308134815C170493617 @default.
- W4308134815 hasConceptScore W4308134815C2776174234 @default.
- W4308134815 hasConceptScore W4308134815C2778938600 @default.
- W4308134815 hasConceptScore W4308134815C555293320 @default.
- W4308134815 hasConceptScore W4308134815C71924100 @default.
- W4308134815 hasConceptScore W4308134815C98274493 @default.
- W4308134815 hasIssue "Supplement_1" @default.
- W4308134815 hasLocation W43081348151 @default.
- W4308134815 hasLocation W43081348152 @default.
- W4308134815 hasOpenAccess W4308134815 @default.
- W4308134815 hasPrimaryLocation W43081348151 @default.
- W4308134815 hasRelatedWork W1970287328 @default.
- W4308134815 hasRelatedWork W2027913950 @default.
- W4308134815 hasRelatedWork W2028293475 @default.
- W4308134815 hasRelatedWork W2050423574 @default.
- W4308134815 hasRelatedWork W2058205365 @default.
- W4308134815 hasRelatedWork W2077993809 @default.
- W4308134815 hasRelatedWork W2101411396 @default.
- W4308134815 hasRelatedWork W2126063009 @default.
- W4308134815 hasRelatedWork W2127396703 @default.
- W4308134815 hasRelatedWork W2135883226 @default.
- W4308134815 hasVolume "6" @default.
- W4308134815 isParatext "false" @default.
- W4308134815 isRetracted "false" @default.
- W4308134815 workType "article" @default.